Haemonetics HAE Cash Flow Statement
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| —— | $167.68M+42.6% | $117.56M+1.9% | $115.4M+166% | ||
| $111.72M-3.3% | $115.59M+18.9% | $97.22M+4.2% | $93.31M-4.5% | ||
| $33.83M+14.1% | $29.64M+4.6% | $28.33M+10.7% | $25.58M+5.0% | ||
| $95.13M— | —— | $10.42M— | —— | ||
| $714K-95.5% | $15.7M+1,450% | $1.01M+7.4% | $943K-90.2% | ||
| $14.88M+314% | -$6.96M— | —— | $24.42M-30.2% | ||
| -$47.36M-173% | $64.7M+7.7% | $60.06M— | —— | ||
| —— | —— | $44.58M+12.0% | $39.82M— | ||
| $10.73M+7.5% | $9.98M-14.2% | $11.63M+24.8% | $9.32M— | ||
| $293.22M+61.4% | $181.73M-0.3% | $182.29M-33.2% | $273.06M+58.5% | ||
| $32.78M-16.5% | $39.28M+3.0% | $38.13M-80.1% | $191.33M+98.2% | ||
| $60.18M— | —— | $243.85M— | —— | ||
| $36.07M+110% | $17.14M+10.2% | $15.55M-53.2% | $33.21M— | ||
| $1.38M-94.1% | $23.25M+1,185% | $1.81M— | —— | ||
| -$179.55M— | —— | -$322.39M-124% | -$143.79M-66.5% | ||
| —— | —— | —— | $75M— | ||
| $0— | —— | $0— | $0— | ||
| $0-100% | $4.69M-61.7% | $12.25M+27.3% | $9.63M-45.0% | ||
| —— | —— | $1.61M-39.0% | $2.64M+12.8% | ||
| $5M-51.2% | $10.24M+74.1% | $5.89M— | $0— | ||
| -$102K+59.0% | -$249K+74.5% | -$976K— | —— | ||
| $0— | —— | $0-100% | $1.12M— | ||
| -$180.49M— | —— | —— | -$100.36M-537% | ||
| —— | —— | —— | —— | ||
| -$64.85M— | —— | -$105.67M-523% | $24.97M-62.8% | ||
| $5.81M-61.1% | $14.96M+347% | $3.35M— | $0— | ||
| $95.13M— | —— | $10.42M— | —— | ||
| -$1.88M+91.8% | -$23.02M— | $0+100% | -$504K— | ||
| $0— | —— | $0— | $0— | ||
| —— | -$226K-123% | $983K— | —— | ||
| $36.07M+110% | $17.14M+10.2% | $15.55M-53.2% | $33.21M— | ||
| $1.38M-94.1% | $23.25M+1,185% | $1.81M— | —— | ||
| -$51.89M-146% | -$21.11M+25.1% | -$28.17M-135% | $81.14M+56.6% | ||
| —— | —— | $0— | $0— | ||
| $0— | —— | $0-100% | $280M— | ||
| $7.89M-5.3% | $8.33M+15.5% | $7.21M+2.8% | $7.02M— | ||
| $0-100% | $88.2M— | $0— | $0— | ||
| $0— | —— | $0-100% | $1.12M— | ||
| —— | —— | —— | —— | ||
| -$102K+59.0% | -$249K+74.5% | -$976K-2,118% | -$44K— | ||
| —— | —— | —— | —— | ||
| $300M+61.7% | $185.5M— | $0— | —— | ||
| $0— | —— | $60M+20.0% | $50M— | ||
| $0-100% | $250M— | $0-100% | $280M— | ||
| $47.26M— | $0— | $0— | —— | ||
| $35.81M— | $0— | $0— | —— | ||
| $260.44M+82.8% | $142.45M— | —— | —— | ||
| $260.44M+82.8% | $142.45M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Haemonetics's cash flow data come from?
- Every line is extracted from Haemonetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.